MBMark E. Berres

Mark E. Berres

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mark E. Berres has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A single day of reduced activity alters the next day’s transcriptomic and metabolic exercise response

    by Kevin J. Gries, Joseph E. McGraw, Emily C. Goetz-Sutinen, Jessica L. Grimm, Jonathan B. Baranowski, Mark E. Berres

    This investigation shows modest differences in the metabolic demands of an acute bout of exercise following a day of inactivity. In addition, there are differences in the skeletal muscle transcriptome at rest and in the exercise response with decreased physical activity before exercise. This study highlights the need for more research on the role of physical inactivity in the exercise response, as well as the need to control for step count before exercise response studies.


  • Open Access

    The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool

    by Alex C Veith, Jennifer J Meudt, Jamie L Reichert, Jennifer M Frank, Derek M Pavelec, Bridget Ladell, James Speers, Molly Zeller, Taeyoung Shin, Joshua R Hyman, et al.

    Porcine biomedical models have emerged as valuable tools in biomedical research due to their physiological, anatomical, metabolic, immunological, and genetic similarities to humans. As a result, they offer greater relevance for translational studies than rodent models. Moreover, compared to nonhuman primates, porcine models are more cost-effective, easier to manipulate genetically, and raise fewer ethical concerns. However, the conventional breeds of swine most commonly used in research have rapid growth rates, which lead to logistical challenges such as increased space requirements, making them impractical as biomedical models. The Wisconsin Miniature SwineTM (WMSTM) was developed to address these shortcomings. The WMSTM porcine model grows slower, reaching and maintaining human sizes at adulthood. The model was also specifically designed to possess more human-like physiology that allows for easy modeling of comorbidities like obesity and metabolic syndrome that affect a large portion of the human population affected by chronic diseases. Thus, WMS™ is an ideal porcine gene editing platform for modeling complex multifactorial diseases. Here, we present the first draft genome assembly representative of the WMSTM line. The primary assembly was generated with ∼20× coverage of long reads from Oxford Nanopore Technologies and independently error-corrected using 23× Pacific Biosciences reads. Arima Genomics Hi-C data were used to improve contiguity. Largely congruent with the existing Sus scrofa genome, we also show the utility of WMSTM as a model through comparisons between 2 WMSTM genes and human homologs. Finally, we show the utility of genotyping by sequencing across WMSTM herds. The WMSTM genome generated here is highly complete and supports investigators utilizing WMSTM in biomedical research.


  • Open Access

    duperis a null mutation of Cryptochrome 1 in Syrian hamsters

    by Yin Yeng Lee, Sibel Cal-Kayitmazbatir, Lauren J. Francey, Michael Seifu Bahiru, Katharina E. Hayer, Gang Wu, Molly J. Zeller, Robyn Roberts, James Speers, Justin Koshalek, et al.

    Significance: We successfully identified theduperallele as a null mutation of Cryptochrome 1 in Syrian hamsters. Here, we have shown the use of fast homozygosity mapping as an effective approach to identify causal mutations in mammals, despite lacking chromosomal genome information. In the course of this work, we improved the draft Syrian hamster genome and generated datasets necessary to exploit Syrian hamsters as a modern genetic research model. The unique physiological features of Syrian hamsters make them a desirable model to investigate human diseases, including circadian disorders, cancer, heart function, metabolism, and infectious diseases (e.g., severe acute respiratory syndrome coronavirus 2).